The FDA has issued emergency use authorizations for two monoclonal antibody treatments for COVID-19 – one produced by Eli Lilly and another by Regeneron. As science correspondent Richard Harris explains, emergency use authorization doesn't assure that these new drugs are effective, but that their potential benefits are likely to outweigh the risks. So today, we get to the bottom of how this type of treatment works and if they'll really make a difference.Email the show your questions, coronavirus or otherwise, at [email protected] more about sponsor message choices: podcastchoices.com/adchoicesNPR Privacy Policy
No persons identified in this episode.
No transcription available yet
Help us prioritize this episode for transcription by upvoting it.
Popular episodes get transcribed faster